

Ming Hou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/651666/publications.pdf>

Version: 2024-02-01

140
papers

4,014
citations

147566

31
h-index

143772

57
g-index

146
all docs

146
docs citations

146
times ranked

3248
citing authors

#	ARTICLE	IF	CITATIONS
1	Atorvastatin restores imbalance of cluster of differentiation 4 (CD4) ⁺ T cells in immune thrombocytopenia <i>in vivo</i> and <i>in vitro</i> . <i>British Journal of Haematology</i> , 2023, 201, 530-541.	1.2	7
2	Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study. <i>Platelets</i> , 2022, 33, 82-88.	1.1	17
3	Global burden and attributable risk factors of acute lymphoblastic leukemia in 204 countries and territories in 1990–2019: Estimation based on Global Burden of Disease Study 2019. <i>Hematological Oncology</i> , 2022, 40, 93-105.	0.8	4
4	Dose tapering to withdrawal stage and long-term efficacy and safety of eltrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 716-728.	1.9	6
5	Significance of anti-HBc serological status in primary immune thrombocytopenia. <i>British Journal of Haematology</i> , 2022, 196, 1086-1095.	1.2	1
6	Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: A multicenter, randomized, controlled study. <i>American Journal of Hematology</i> , 2022, 97, 440-447.	2.0	4
7	Association of metformin treatment and outcome in adult patients with ITP and pre-existing T2DM. <i>British Journal of Haematology</i> , 2022, , .	1.2	1
8	Clonal hematopoiesis in primary immune thrombocytopenia. <i>Blood Cancer Journal</i> , 2022, 12, 40.	2.8	2
9	Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia. , 2022, 19, 764-776.		10
10	HDAC3 single-nucleotide polymorphism rs2530223 is associated with increased susceptibility and severity of primary immune thrombocytopenia. <i>International Journal of Laboratory Hematology</i> , 2022, , .	0.7	1
11	Human leukocyte antigen-G upregulates immunoglobulin-like transcripts and corrects dysfunction of immune cells in immune thrombocytopenia. <i>Haematologica</i> , 2021, 106, 770-781.	1.7	11
12	Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. <i>Platelets</i> , 2021, 32, 633-641.	1.1	6
13	Immune thrombocytopenia (ITP) World Impact Survey (iWISH): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. <i>American Journal of Hematology</i> , 2021, 96, 188-198.	2.0	55
14	Reduced intracellular antioxidant capacity in platelets contributes to primary immune thrombocytopenia via ROS-NLRP3-caspase-1 pathway. <i>Thrombosis Research</i> , 2021, 199, 1-9.	0.8	15
15	Immune thrombocytopenia (ITP) World Impact Survey (iWISH): Impact of ITP on health-related quality of life. <i>American Journal of Hematology</i> , 2021, 96, 199-207.	2.0	54
16	Identification of a pathogenic TUBB1 variant in a Chinese family with congenital macrothrombocytopenia through whole genome sequencing. <i>Platelets</i> , 2021, 32, 1108-1112.	1.1	2
17	Tumor Necrosis Factor- α Blockade Corrects Monocyte/Macrophage Imbalance in Primary Immune Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021, 121, 767-781.	1.8	12
18	Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia. <i>Frontiers in Immunology</i> , 2021, 12, 630693.	2.2	19

#	ARTICLE	IF	CITATIONS
19	A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 37.	6.9	33
20	Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia. <i>Blood</i> , 2021, 138, 674-688.	0.6	33
21	Immune thrombocytopenia during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2021, 193, 1093-1095.	1.2	6
22	Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e289-e298.	2.2	31
23	Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma. <i>Minerva Medica</i> , 2021, 112, 310-312.	0.3	2
24	Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. <i>British Journal of Haematology</i> , 2021, 194, 191-194.	1.2	8
25	Antihuman CD44 antibody BJ18 inhibits platelet phagocytosis by correcting aberrant FcγR expression and M1 polarization in immune thrombocytopenia. <i>International Immunopharmacology</i> , 2021, 95, 107502.	1.7	3
26	Predictive Value of High ICAM-1 Level for Poor Treatment Response to Low-Dose Decitabine in Adult Corticosteroid Resistant ITP Patients. <i>Frontiers in Immunology</i> , 2021, 12, 689663.	2.2	5
27	Proteomic analysis and microRNA expression profiling of plasma-derived exosomes in primary immune thrombocytopenia. <i>British Journal of Haematology</i> , 2021, 194, 1045-1052.	1.2	10
28	Regulation of megakaryopoiesis by bone marrow macrophage polarization. <i>Blood Science</i> , 2021, 3, 149-150.	0.4	1
29	Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. <i>Blood Advances</i> , 2021, 5, 4087-4101.	2.5	13
30	Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019. <i>JCO Global Oncology</i> , 2021, 7, 1429-1441.	0.8	13
31	Clinical and molecular features of Epstein-Barr virus-positive diffuse large B-cell lymphoma: Results in a multicenter trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e539.	1.7	5
32	All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e688-e699.	2.2	19
33	NLRP3-activated bone marrow dendritic cells play antileukemic roles via IL-1 ² /Th1/IFN- ³ in acute myeloid leukemia. <i>Cancer Letters</i> , 2021, 520, 109-120.	3.2	10
34	A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. <i>Frontiers in Oncology</i> , 2021, 11, 750323.	1.3	12
35	First line treatment of adult patients with primary immune thrombocytopenia: a real-world study. <i>Platelets</i> , 2020, 31, 55-61.	1.1	11
36	Interleukin-37 reduces inflammation and impairs phagocytosis of platelets in immune thrombocytopenia (ITP). <i>Cytokine</i> , 2020, 125, 154853.	1.4	10

#	ARTICLE	IF	CITATIONS
37	Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-Risk Myelodysplastic Syndromes. <i>Annals of Internal Medicine</i> , 2020, 172, 513.	2.0	78
38	High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial. <i>American Journal of Hematology</i> , 2020, 95, 1542-1552.	2.0	39
39	A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. <i>Blood Advances</i> , 2020, 4, 5846-5857.	2.5	5
40	miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 764-776.	2.3	28
41	The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. <i>Hematology</i> , 2020, 25, 139-144.	0.7	14
42	A reply to Demirci <i>et al</i> .. <i>American Journal of Hematology</i> , 2020, 95, E104.	2.0	0
43	Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. <i>Blood</i> , 2020, 135, 472-490.	0.6	102
44	Co-Inhibition of the Immunoproteasome Subunits LMP2 and LMP7 Ameliorates Immune Thrombocytopenia. <i>Frontiers in Immunology</i> , 2020, 11, 603278.	2.2	3
45	Immune Checkpoint-Related Gene Polymorphisms Are Associated With Primary Immune Thrombocytopenia. <i>Frontiers in Immunology</i> , 2020, 11, 615941.	2.2	23
46	791...A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL). , 2020, , .		1
47	Risk and Prognostic Factors for Intracranial Hemorrhage in Elderly Patients with Immune Thrombocytopenia. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
48	Outcome of CARE: a 6-year national registry of acquired haemophilia A in China. <i>British Journal of Haematology</i> , 2019, 187, 653-665.	1.2	28
49	A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia. <i>American Journal of Hematology</i> , 2019, 94, 1374-1381.	2.0	39
50	All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1 β loop. <i>Haematologica</i> , 2019, 104, 1661-1675.	1.7	25
51	Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial. <i>Lancet Haematology</i> , 2019, 6, e328-e337.	2.2	31
52	High-Dose Dexamethasone Alters the Increase in Interleukin-16 Level in Adult Immune Thrombocytopenia. <i>Frontiers in Immunology</i> , 2019, 10, 451.	2.2	7
53	Aberrant expression of microRNA in CD4+ cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia. <i>Thrombosis Research</i> , 2019, 177, 70-78.	0.8	23
54	PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 758-765.	1.8	21

#	ARTICLE	IF	CITATIONS
55	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3780-3817.	2.5	593
56	Disrupted balance of CD4+ T-cell subsets in bone marrow of patients with primary immune thrombocytopenia. <i>International Journal of Biological Sciences</i> , 2019, 15, 2798-2814.	2.6	30
57	Laparoscopic hysterectomy in chronic renal failure patients with abnormal uterine bleeding. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2019, 28, 41-45.	0.6	1
58	Effect of recombinant human thrombopoietin on immune thrombocytopenia in pregnancy in a murine model. <i>International Immunopharmacology</i> , 2019, 67, 287-293.	1.7	11
59	Indirubin modulates CD4 ⁺ T cell homeostasis via PD1/PTEN/AKT signalling pathway in immune thrombocytopenia. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1885-1898.	1.6	25
60	Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: A multi-center prospective observational study. <i>Thrombosis Research</i> , 2019, 173, 20-26.	0.8	40
61	Novel Murine Model of Immune Thrombocytopaenia through Immunized CD41 Knockout Mice. <i>Thrombosis and Haemostasis</i> , 2019, 119, 377-383.	1.8	10
62	Reproductive and developmental toxicity study of caffeic acid in mice. <i>Food and Chemical Toxicology</i> , 2019, 123, 106-112.	1.8	35
63	Low-dose chidamide restores immune tolerance in ITP in mice and humans. <i>Blood</i> , 2019, 133, 730-742.	0.6	40
64	High-Dose Dexamethasone (HD-DXM) Plus Oseltamivir Versus High-Dose Dexamethasone for Treatment of Adult Primary Immune Thrombocytopenia: Interim Analysis of a Prospective, Multicenter, Randomized, Controlled Trial. <i>Blood</i> , 2019, 134, 900-900.	0.6	5
65	Combination of ATRA and High-Dose Dexamethasone As First-Line Treatment in Adult Immune Thrombocytopenia: a Randomized, Phase 2, Open-Label Trial. <i>Blood</i> , 2019, 134, 899-899.	0.6	2
66	Bortezomib: Once-Weekly 1.6mg/m ² Maybe a Better Choice Compared with Twice-Weekly 1.3mg/m ² in Newly Dignosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5558-5558.	0.6	0
67	Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China. <i>Blood</i> , 2019, 134, 5914-5914.	0.6	0
68	Physicians' and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISH). <i>Blood</i> , 2019, 134, 1097-1097.	0.6	1
69	Chinese guidelines for treatment of adult primary immune thrombocytopenia. <i>International Journal of Hematology</i> , 2018, 107, 615-623.	0.7	63
70	Progranulin facilitates the increase of platelet count in immune thrombocytopenia. <i>Thrombosis Research</i> , 2018, 164, 24-31.	0.8	1
71	CD4 ⁺ T cell autoantibody predicts better rituximab response in ITP. <i>British Journal of Haematology</i> , 2018, 182, 305-307.	1.2	19
72	Anti-cMpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO. <i>Thrombosis Research</i> , 2018, 170, 200-206.	0.8	14

#	ARTICLE	IF	CITATIONS
73	Proteasome Inhibition with Bortezomib Induces Apoptosis of Long-Lived Plasma Cells in Steroid-Resistant or Relapsed Immune Thrombocytopaenia. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1752-1764.	1.8	26
74	NF- κ B-94ins/del ATG Genotype Contributes to the Susceptibility and Imbalanced Th17 Cells in Patients with Immune Thrombocytopenia. <i>Journal of Immunology Research</i> , 2018, 2018, 1-12.	0.9	8
75	Low platelet count as risk factor for infections in patients with primary immune thrombocytopenia: a retrospective evaluation. <i>Annals of Hematology</i> , 2018, 97, 1701-1706.	0.8	22
76	GPIb α is required for platelet-mediated hepatic thrombopoietin generation. <i>Blood</i> , 2018, 132, 622-634.	0.6	58
77	Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance. <i>Blood Cancer Journal</i> , 2018, 8, 61.	2.8	10
78	Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. <i>Blood</i> , 2018, 131, 787-796.	0.6	54
79	Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Teleso Study. <i>Blood</i> , 2018, 132, 234-234.	0.6	26
80	Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-WISH). <i>Blood</i> , 2018, 132, 2273-2273.	0.6	14
81	Results from the ITP World IMPACT Survey (I-WISH): Patients with Immune Thrombocytopenia (ITP) Experience Impaired Quality of Life (QoL) Regarding Daily Activities, Social Interactions, Emotional Well-Being and Working Lives. <i>Blood</i> , 2018, 132, 4804-4804.	0.6	4
82	Detection of a New NFKB1 Frameshift Mutation Associated with Primary Immunodeficiency Diseases. <i>Blood</i> , 2018, 132, 2416-2416.	0.6	0
83	High-Dose Dexamethasone Corrects the Elevated Level of IL-16 in Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 2431-2431.	0.6	5
84	PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis. <i>Blood</i> , 2018, 132, 3700-3700.	0.6	0
85	Atorvastatin Restored the CD4+ T Cell Homeostasis By Regulating the Axis of Effector T Cells and Regulatory T Cells in Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 132-132.	0.6	8
86	18 β -Glycyrrhetic Acid Modulates Th1/Th17/Th22/Regulatory T Cells Homeostasis Via HMGB1/NF- κ B Signaling Pathway in Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 1144-1144.	0.6	2
87	Aberrant Expression of MicroRNAs in CD4+ Cells May Contribute to the Imbalance of Th17/Treg Cells in Primary Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 1140-1140.	0.6	0
88	Human Leukocyte Antigen-G Restores Immune Tolerance in Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 3751-3751.	0.6	0
89	Efficacy and Safety of Eltrombopag in Chinese Patients with Chronic Immune Thrombocytopenia: Stage 2 Results from a Multicenter Phase III Study. <i>Blood</i> , 2018, 132, 3760-3760.	0.6	0
90	Abnormal Microenvironment of Bone Marrow B Lymphocytes in Patients with Primary Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 3759-3759.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia. <i>Cytokine</i> , 2017, 92, 110-117.	1.4	18
92	JIP3 regulates neuronal radial migration by mediating TrkB axonal anterograde transport in the developing cerebral cortex. <i>Biochemical and Biophysical Research Communications</i> , 2017, 485, 790-795.	1.0	4
93	Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 46.	6.9	48
94	Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2017, 10, 104.	6.9	49
95	A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. <i>Blood</i> , 2017, 130, 1097-1103.	0.6	82
96	SAG5B and SAG5C combined vaccine protects mice against <i>Toxoplasma gondii</i> infection. <i>Parasitology International</i> , 2017, 66, 596-602.	0.6	13
97	Genetic polymorphisms of IL-18 rs1946518 and IL-1 β rs16944 are associated with prognosis and survival of acute myeloid leukemia. <i>Inflammation Research</i> , 2017, 66, 249-258.	1.6	27
98	Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e487-e496.	2.2	38
99	Pre-synaptic TrkB in basolateral amygdala neurons mediates BDNF signaling transmission in memory extinction. <i>Cell Death and Disease</i> , 2017, 8, e2959-e2959.	2.7	11
100	JIP1 and JIP3 cooperate to mediate TrkB anterograde axonal transport by activating kinesin-1. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 4027-4044.	2.4	33
101	Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. <i>British Journal of Haematology</i> , 2017, 176, 101-110.	1.2	55
102	TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy. <i>Immunological Investigations</i> , 2017, 46, 172-182.	1.0	40
103	Inflammation-Related Gene Polymorphisms Associated With Primary Immune Thrombocytopenia. <i>Frontiers in Immunology</i> , 2017, 8, 744.	2.2	32
104	Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy. <i>Oncotarget</i> , 2016, 7, 7489-7496.	0.8	15
105	Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsed primary immune thrombocytopenia. <i>Open Medicine (Poland)</i> , 2016, 11, 97-100.	0.6	1
106	Pulsed high-dose dexamethasone modulates Th1-/Th2-chemokine imbalance in immune thrombocytopenia. <i>Journal of Translational Medicine</i> , 2016, 14, 301.	1.8	14
107	CD8+ T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. <i>Scientific Reports</i> , 2016, 6, 27445.	1.6	61
108	T cells in the pathogenesis of immune thrombocytopenia. <i>Seminars in Hematology</i> , 2016, 53, S13-S15.	1.8	18

#	ARTICLE	IF	CITATIONS
109	High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. <i>Blood</i> , 2016, 127, 296-302.	0.6	165
110	Thrombopoietin receptor agonists shift the balance of Fc γ 3 receptors toward inhibitory receptor IIb on monocytes in ITP. <i>Blood</i> , 2016, 128, 852-861.	0.6	62
111	CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fc γ 3 Receptor- and Complement Receptor 3-Dependent Mechanisms. <i>Journal of Immunology</i> , 2016, 196, 3331-3340.	0.4	25
112	A Prospective Multicenter Single-Arm Study of Low-Dose Decitabine in Adult Patients with Immune Thrombocytopenia. <i>Blood</i> , 2016, 128, 3744-3744.	0.6	0
113	Interleukin-17A and -17F Gene Polymorphisms in Chinese Population with Chronic Immune Thrombocytopenia. <i>Annals of Clinical and Laboratory Science</i> , 2016, 46, 291-7.	0.2	9
114	A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. <i>Blood</i> , 2015, 125, 1541-1547.	0.6	100
115	Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. <i>Blood</i> , 2015, 125, 2771-2778.	0.6	102
116	Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1021-1034.	1.8	45
117	Imbalance between CD205 and CD80/CD86 in dendritic cells in patients with immune thrombocytopenia. <i>Thrombosis Research</i> , 2015, 135, 352-361.	0.8	9
118	Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. <i>Nature Communications</i> , 2015, 6, 7737.	5.8	258
119	Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia. <i>Clinical Therapeutics</i> , 2015, 37, 1382-1395.	1.1	11
120	Decreased Tim-3 and its correlation with Th1 cells in patients with immune thrombocytopenia. <i>Thrombosis Research</i> , 2014, 133, 52-56.	0.8	15
121	Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia. <i>Blood</i> , 2014, 124, 3316-3319.	0.6	29
122	Effect of Eltrombopag on Platelet Response and Safety Results in Chinese Adults with Chronic ITP-Primary Result of a Phase III Study. <i>Blood</i> , 2014, 124, 1464-1464.	0.6	6
123	Platelet Desialylation Is Closely Associated with Cytotoxic T Lymphocyte-Mediated Platelet Destruction in Immune Thrombocytopenia. <i>Blood</i> , 2014, 124, 463-463.	0.6	3
124	Platelet Desialylation: A Novel Mechanism of Fc-Independent Platelet Clearance and a Potential Diagnostic Biomarker and Therapeutic Target in immune Thrombocytopenia. <i>Blood</i> , 2014, 124, 467-467.	0.6	1
125	Recombinant Human Thrombopoietin: a Novel Therapeutic Option for Patients with Immune Thrombocytopenia in Pregnancy. <i>Blood</i> , 2014, 124, 5005-5005.	0.6	2
126	Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis. <i>PLoS ONE</i> , 2014, 9, e95473.	1.1	8

#	ARTICLE	IF	CITATIONS
127	Conventional Oral Prednisone Versus High-Dose Dexamethasone for Management of Adult Immune Thrombocytopenia: A Prospective Randomized Multicenter Clinical Trial. <i>Blood</i> , 2014, 124, 1455-1455.	0.6	1
128	Recombinant Human Thrombopoietin and Rituximab vs Rituximab Monotherapy in Corticosteroid-Resistant Primary Immune Thrombocytopenia: a Multicenter Randomized Controlled Study. <i>Blood</i> , 2013, 122, 329-329.	0.6	1
129	Sustained Complete Remission Of Corticosteroid-Resistant Immune Thrombocytopenia With a Short Course Of Recombinant Human Thrombopoietin. <i>Blood</i> , 2013, 122, 4746-4746.	0.6	1
130	A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. <i>International Journal of Hematology</i> , 2012, 96, 222-228.	0.7	77
131	Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIb/IIIa versus GPIIb/IIIa antibodies. <i>American Journal of Hematology</i> , 2012, 87, 206-208.	2.0	85
132	Human and Murine Immune Thrombocytopenia (ITP) Is Associated with a Peripheral Deficiency of CD4+ T Regulatory Cells (Tc-regs). <i>Blood</i> , 2012, 120, 3333-3333.	0.6	1
133	A 15 Mg/M2/d Dose of Decitabine Confers Comparable Responses and Better Tolerance Than the Standard Regimen in MDS patients—results of a Multicenter Prospective Cohort Study. <i>Blood</i> , 2012, 120, 3832-3832.	0.6	0
134	Recombinant Human Thrombopoietin (rh-TPO) in Combination with Rituximab As a Novel Therapy in Corticosteroid-Resistant Primary Immune Thrombocytopenia (ITP). <i>Blood</i> , 2011, 118, 2223-2223.	0.6	0
135	Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. <i>Blood</i> , 2010, 116, 4307-4316.	0.6	67
136	Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. <i>Haematologica</i> , 2009, 94, 1326-1329.	1.7	121
137	Profile of Th17 cytokines (IL-17, TGF- β 2, IL-6) and Th1 cytokine (IFN- γ 3) in patients with immune thrombocytopenic purpura. <i>Annals of Hematology</i> , 2008, 87, 899-904.	0.8	69
138	Cell-Based Immunotherapy with Different Subsets of Tolerogenic Dendritic Cell in Idiopathic Thrombocytopenic Purpura.. <i>Blood</i> , 2008, 112, 3408-3408.	0.6	0
139	Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. <i>European Journal of Haematology</i> , 2003, 70, 353-357.	1.1	122
140	Both splenic CD5+ B and CD5 α ~ B cells produce platelet glycoprotein-specific autoantibodies in chronic ITP. <i>Thrombosis Research</i> , 2003, 110, 1-5.	0.8	13